Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the HIV Drugs Industry?

In recent times, the market size of HIV drugs has seen a stable escalation. It’s predicted to swell from a substantial $35.33 billion in 2024 to an even more impressive $36.55 billion in 2025, boasting a compound annual growth rate (CAGR) of 3.5%. Several factors have contributed to this expansion during the historic period, including heightened governmental support and initiatives, an upswing in healthcare costs, a surge in funds allocated to HIV research and development, an increased occurrence of HIV infections, and a spike in awareness and economic development in emerging markets.

The market size for HIV drugs is poised for consistent expansion over the forthcoming years. It’s projected to reach a size of “$41.55 billion in 2029 with a compound annual growth rate (CAGR) of 3.3%.” This growth trajectory during the forecast period can be ascribed to several factors such as growing governmental backing and initiatives, increase in healthcare spending, a surge in HIV-related research and development expenditure, rising incidences of HIV infections, heightened awareness, and economic growth in emerging markets. The forecast period also sees some dominant trends such as investments in 3D bioprinting technology, introduction of novel product innovations, the development of combination products across different classes for HIV therapy, and investing in strategic alliances and partnerships.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2834&type=smp

What Forces Are Driving The Growth Of The HIV Drugs Industry?

The increasing recognition of HIV diagnosis and treatment protocols plays a crucial role in propelling the HIV drug market’s expansion. HIV/AIDS is among the most persistent diseases, with a high incidence rate worldwide, leading to an unparalleled familiarity with the disease. For example, data from UNICEF, a US-based humanitarian aid organization, in July 2024, showed that in 2023, the global HIV positive population was approximately 40.0 million, including 2.38 million children between the ages of 0-19. In the same year, around 685 children were infected with HIV every day, and about 250 kids died from AIDS. Thus, escalating cognizance surrounding HIV diagnosis and treatment is a key driving force behind the HIV drug market’s growth.

The hiv drugs market covered in this report is segmented –

1) By Type: Nucleoside Reverse Transcriptase Inhibitors (NRT’s), Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s), Protease Inhibitors, Integrase strand transfer inhibitors (INSTIs), Other Types

2) By Administration: Oral, Parenteral

3) By Application: Hospital Pharmacies, Retail Pharmacies, Other Applications

Subsegments:

1) By Nucleoside Reverse Transcriptase Inhibitors (NRTIs): Zidovudine (AZT), Lamivudine (3TC), Abacavir (ABC), Tenofovir disoproxil fumarate (TDF), Other NRTIs

2) By Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Efavirenz (EFV), Nevirapine (NVP), Etravirine (ETR), Rilpivirine (RPV), Other NNRTIs

3) By Protease Inhibitors (PIs): Ritonavir (RTV), Lopinavir (LPV), Darunavir (DRV), Atazanavir (ATV), Other PIs

4) By Integrase Strand Transfer Inhibitors (INSTIs): Raltegravir (RAL), Dolutegravir (DTG), Bictegravir (BIC), Other INSTIs

5) By Other Types: Entry Inhibitors, Fusion Inhibitors, Combination Therapies

What Future Market Trends Are Projected For The HIV Drugs Industry?

Prominent players in the HIV drugs market are forming key alliances to produce Lenacapavir with the aim to speed up drug development, broaden treatment access, and fortify their worldwide market position. Lenacapavir, a first-of-its-kind HIV-1 capsid inhibitor, works in conjunction with other antiretrovirals and targets several HIV lifecycle stages, making it a promising route for patients with limited treatment options. For example, in August 2023, Dr. Reddy’s Laboratories and Hetero, both pharmaceutical companies based in India, entered into a partnership with Gilead Sciences Inc. Through this alliance, Dr. Reddy’s Laboratories and Hetero plan to produce and distribute the HIV drug lenacapavir in predominantly 120 low- and lower-middle-income countries (LMICs). This initiative is aimed at widening the access to this unique treatment, which is extremely beneficial for patients with multi-drug-resistant HIV who have heavy treatment experience. Gilead Sciences Inc. is a biopharmaceutical company based in the US.

Who Are The Primary Players Operating Across The Global HIV Drugs Market?

Major companies operating in the HIV drugs market include Gilead Sciences Inc., Johnson & Johnson, Merck & Co. Inc., Boehringer Ingelheim International GmbH, Cipla, Aurobindo Pharma, AbbVie, Emcure Pharmaceuticals, Micro Labs Limited, Northeast Pharmaceutical Group Co. Ltd, Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd, Strides Arcolab Limited, Hetero Labs Limited, Shanghai Desano Bio-pharmaceutical Co., Anhui Biochem Biopharmaceutical Co. Ltd., China’s National Health Commission (NHC), Shanghai Xinxing Medicine Co. Ltd., China Meheco Xinxing Pharma Co. Ltd., CytoDyn Inc., Janssen Pharmaceutical, Bavarian Nordic, Roche Laboratories, Pharmstandard, Pharmasyntez, R-Pharm, Alium, ChemRar Group, Gritstone Oncology, Enzolytics Inc., BioClonetics Immunotherapeutics Inc., Dewpoint Therapeutics, Lyndra Therapeutics, Mylan N.V., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Teva Canada, ViiV Healthcare Canada, GSK, Abbott Laboratories, Aspen Pharmacare Limited, Pharmacare Ltd.

https://www.thebusinessresearchcompany.com/report/hiv-drug-global-market-report

Which Region Offers The Most Growth Potential For The HIV Drugs Market Through 2029?

North America was the largest region in the HIV drugs market share in 2024. Middle East is expected to be the largest growing region in the global HIV drug market during the forecast period. The regions covered in the HIV drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=2834&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model